Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-736-8 | CAS number: 149-30-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Neurotoxicity
Administrative data
Description of key information
Key value for chemical safety assessment
Additional information
The neurotoxic potential of MBT was evaluated in an acute and subchronic neurotoxicity studies.
In the acute neurotoxicity study (CMA 1989) male and female Sprague-Dawley rats (12 per sex and dose) were dosed once by gavage with MBT at doses of 0, 500, 1250 or 2750 mg/kg bw/kg. The animals were observed for 14 days.
Motor activity testing and a functional observational battery were performed pre-study, at approximately 1, 6 and 24 hours post-dosing and on observation days 7 and 14. Motor activity testing was conducted pre-study and at approximately 12 hours following treatment during the dark phase of the light/dark cycle. Animals were subjected to a gross pathological examination at the completion of the study.
One high dose female rat died just prior to placement in the activity monitor (ca. 12 hours post-dosing). Prior to death, the animal was cold and showed signs of muzzle straining, salivation and decreased respiration. Males in the 2750 mg MBT/kg group and females in all MBT treated groups displayed an increase of muzzle staining during the first week, following treatment. This was an occasion accompanied by salivation. A significantly greater weight loss for males and a larger weight loss for females in the 2750 mg MBT/kg group compared to the control group occurred from day 0 (day of treatment) to day 1. The functional observational battery (FOB) revealed several transitory differences. These included an increased incidence of salivation at the 1 h assessment for males in the 2750 mg MBT/kg group and females in the 500, 1250 and 2750 mg MBT/kg groups, decreases in vocalization for males in the 1250 and 2750 mg/kg groups at 1 and 6 h observations, and an increased incidence of urinary staining for females in the 2750 mg/kg group at the 24 h assessment. Grip strength and hindlimb splay were unaffected by treatment with MBT. The motor activity test performed at ca. 12 h post-dosing showed significantly (P< 0.01) decreased activity levels for males in the 2750 mg/kg group and for females in the 1250 and 2750 mg MBT/kg groups. No pathological findings were seen at necropsy that could be related to treatment with MBT.
The authors suggested that the changes indicated did not give a clear indication of neurotoxicity. While the motor activity test did show decreased activity levels, for the most part, the differences found using the functional observational battery (FOB) were clinical observations typically associated with overt generalized toxicity. Assessments for CNS disorders (tremors, convulsions, bizarre behaviour), muscle tone and equilibrium (body and abdominal tones, grip strength, hindlimb splay, gait, air righting reflex), and sensory functions (olfactory response, visual placing, auricular startle, tail and toe pinch responses) gave negative findings. The pattern of effects seen was considered attributable to an acute non-specific toxicity without apparent neurotoxicity.
In a subchronic neurotoxicity study (CMA 1990) male and female Sprague-Dawley rats (12 per sex and dose) were feed with 0, 5000, 15000, 25000 ppm (ca. 0, 333, 1000, 1667 mg/kg bw/d) MBT in the diet for 13 weeks. A control group was handled in an identical manner, except that it was given untreated diet. The animals were examined using a functional observation battery (FOB) pre-study, at ca. 1, 6 and 24 hours post-feeding and on days 7, 14, 35, 64 and 91. Motor activity testing was conducted pre-test and on days 29, 63 and 90. Six animals per sex per group were perfused for neuropathology evaluations which were performed on the control and 25000 ppm MBT groups. The remaining 6 animals/sex in each group were subjected to a gross pathological examination.
There were no deaths or adverse clinical signs related to treatment with MBT. There was an initial significant weight loss in the15000 and 25000 ppm groups for both males and females. The body weights of the females in the 15000 ppm group and of males and females in the 25000 ppm group were significantly lower for most or all of the assessment occasions during the study. Initial reductions in food intake occurred for male and females in the 15000 and 25000 ppm groups. Subsequently, values for females were decreased during the second month of treatment and for males in the last week of the study. There were no effects upon behaviour in the qualitative or quantitative (grip strength and hind limb spray) functional observational battery assessment. The motor activity test revealed no treatment related affects. Neither gross nor neuropathological evaluations revealed any treatment related changes.
The authors concluded that treatment of male and female rats for 13 weeks with MBT by dietary incorporation, at levels of up to 25000 ppm resulted in significant effects upon body weight at the 25000 ppm level for males and at the 15000 ppm and 25000 ppm levels for females. Effects upon food intake were primarily transitory, occurring in the first week of the study except for females at the 25000 ppm level where the food intake was significantly decreased during the second week and in the second month of the study. The behavioural (functional observational battery and motor activity test) and neuropathological evaluations produced no evidence of neurotoxicity.
Justification for classification or non-classification
No classification is required according to the classification criteria 67/548/EWG and regulation no. 1272/2008 (GHS).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.